Raman Parthasarathy, Business Unit Head, Fusemachines
Of the many industries witnessing AI-led transformation, healthcare happens to be one. Today, AI’s promise in healthcare extends beyond automation-led operational and administrative efficiencies. It’s beginning to show a…
Continue Reading
How Are Threat Actors Using Generative AI?“We were able to trick a generative AI model to develop highly convincing phishing emails in just five minutes,” Carruthers notes in an IBM SecurityIntelligence blog post. “It…
Continue Reading
Welcome to an inspiring journey through the eyes of Amir Kishon, CEO of Twig Health and a veteran digital health entrepreneur with a remarkable 25-year track record in the field.In this exclusive interview, Amir…
Continue Reading
The following is a guest article by Steve Gwizdala, VP of Healthcare at Ping Identity
The healthcare security landscape has become an increasingly critical concern. According to the 2023 ForgeRock Breach Report, healthcare has consistently…
Lawrence Whittle, President of Verana Health
Artificial intelligence (AI) can be a sensitive subject for some healthcare professionals, and rightfully so. It was not too long ago that IBM’s Watson supercomputer won on “Jeopardy!” The…
Continue Reading
The term knowledge graph may not be part of your everyday vocabulary, but if you are interested in digital health, it’s worth taking a closer look.
By John Halamka, M.D., President, Mayo Clinic Platform and…
Continue Reading
What You Should Know:
– IBM and Meta announced the launch of the AI Alliance, a newly formed group of leading organizations dedicated to fostering open innovation and open science in artificial intelligence with Cleveland…
Continue Reading
Collaborating for biologic breakthroughs, IBM and Boehringer Ingelheim merge genAI with foundation models. IBM’s cutting-edge AI expedites antibody discovery, targeting diseases like cancer, autoimmune disorders, and infections. Boehringer’s validation of refined antibodies affirms in-silico…
Continue Reading
German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery.The partnership leverages IBM’s foundation model technologies, consisting of…
Continue Reading
What You Should Know:
– Boehringer Ingelheim and IBM announced a collaboration to leverage IBM’s foundation model technologies for the discovery of novel candidate antibodies in drug development.
– The partnership will focus on utilizing IBM’s…
Continue Reading
